Family-focused therapy

Bipolar adolescents with comorbid ADHD who received FFT-A showed reductions in family conflict that converged with the non-ADHD group by the end of the study, while those with ADHD in EC continued to

Effect: improvement; F(6,382)=2.29

Bipolar adolescents with comorbid ADHD who received FFT-A showed reductions in family conflict that converged with the non-ADHD group by the end of the study, while those with ADHD in EC continued to

Effect: improvement; F(6,382)=2.29

Bipolar adolescents with comorbid ADHD who received FFT-A showed reductions in family conflict that converged with the non-ADHD group by the end of the study, while those with ADHD in EC continued to

Effect: improvement; F(6,382)=2.29

Bipolar adolescents with comorbid ADHD who received FFT-A showed reductions in family conflict that converged with the non-ADHD group by the end of the study, while those with ADHD in EC continued to

Effect: improvement; F(6,382)=2.29

Bipolar adolescents with comorbid ADHD who received FFT-A showed reductions in family conflict that converged with the non-ADHD group by the end of the study, while those with ADHD in EC continued to

Effect: improvement; F(6,382)=2.29

Bipolar adolescents with comorbid ADHD who received FFT-A showed reductions in family conflict that converged with the non-ADHD group by the end of the study, while those with ADHD in EC continued to

Effect: improvement; F(6,382)=2.29

Bipolar adolescents with comorbid ADHD who received FFT-A showed reductions in family conflict that converged with the non-ADHD group by the end of the study, while those with ADHD in EC continued to

Effect: improvement; F(6,382)=2.29

Bipolar adolescents with comorbid ADHD who received FFT-A showed reductions in family conflict that converged with the non-ADHD group by the end of the study, while those with ADHD in EC continued to

Effect: improvement; F(6,382)=2.29

Bipolar adolescents with comorbid ADHD who received FFT-A showed reductions in family conflict that converged with the non-ADHD group by the end of the study, while those with ADHD in EC continued to

Effect: improvement; F(6,382)=2.29

Bipolar adolescents with comorbid ADHD who received FFT-A showed reductions in family conflict that converged with the non-ADHD group by the end of the study, while those with ADHD in EC continued to

Effect: improvement; F(6,382)=2.29

Bipolar adolescents with comorbid ADHD who received FFT-A showed reductions in family conflict that converged with the non-ADHD group by the end of the study, while those with ADHD in EC continued to

Effect: improvement; F(6,382)=2.29

Bipolar adolescents with comorbid ADHD who received FFT-A showed reductions in family conflict that converged with the non-ADHD group by the end of the study, while those with ADHD in EC continued to

Effect: improvement; F(6,382)=2.29

Bipolar adolescents with comorbid ADHD who received FFT-A showed reductions in family conflict that converged with the non-ADHD group by the end of the study, while those with ADHD in EC continued to

Effect: improvement; F(6,382)=2.29

Bipolar adolescents with comorbid ADHD who received FFT-A showed reductions in family conflict that converged with the non-ADHD group by the end of the study, while those with ADHD in EC continued to

Effect: improvement; F(6,382)=2.29

Bipolar adolescents with comorbid ADHD who received FFT-A showed reductions in family conflict that converged with the non-ADHD group by the end of the study, while those with ADHD in EC continued to

Effect: improvement; F(6,382)=2.29

Bipolar adolescents with comorbid ADHD who received FFT-A showed reductions in family conflict that converged with the non-ADHD group by the end of the study, while those with ADHD in EC continued to

Effect: improvement; F(6,382)=2.29

Bipolar adolescents with comorbid ADHD who received FFT-A showed reductions in family conflict that converged with the non-ADHD group by the end of the study, while those with ADHD in EC continued to

Effect: improvement; F(6,382)=2.29

Bipolar adolescents with comorbid ADHD who received FFT-A showed reductions in family conflict that converged with the non-ADHD group by the end of the study, while those with ADHD in EC continued to

Effect: improvement; F(6,382)=2.29

Bipolar adolescents with comorbid ADHD who received FFT-A showed reductions in family conflict that converged with the non-ADHD group by the end of the study, while those with ADHD in EC continued to

Effect: improvement; F(6,382)=2.29

Bipolar adolescents with comorbid ADHD who received FFT-A showed reductions in family conflict that converged with the non-ADHD group by the end of the study, while those with ADHD in EC continued to

Effect: improvement; F(6,382)=2.29

Bipolar adolescents with comorbid ADHD who received FFT-A showed reductions in family conflict that converged with the non-ADHD group by the end of the study, while those with ADHD in EC continued to

Effect: improvement; F(6,382)=2.29

Bipolar adolescents with comorbid ADHD who received FFT-A showed reductions in family conflict that converged with the non-ADHD group by the end of the study, while those with ADHD in EC continued to

Effect: improvement; F(6,382)=2.29

Bipolar adolescents with comorbid ADHD who received FFT-A showed reductions in family conflict that converged with the non-ADHD group by the end of the study, while those with ADHD in EC continued to

Effect: improvement; F(6,382)=2.29

Bipolar adolescents with comorbid ADHD who received FFT-A showed reductions in family conflict that converged with the non-ADHD group by the end of the study, while those with ADHD in EC continued to

Effect: improvement; F(6,382)=2.29

Bipolar adolescents with comorbid ADHD who received FFT-A showed reductions in family conflict that converged with the non-ADHD group by the end of the study, while those with ADHD in EC continued to

Effect: improvement; F(6,382)=2.29

Bipolar adolescents with comorbid ADHD who received FFT-A showed reductions in family conflict that converged with the non-ADHD group by the end of the study, while those with ADHD in EC continued to

Effect: improvement; F(6,382)=2.29

Bipolar adolescents with comorbid ADHD who received FFT-A showed reductions in family conflict that converged with the non-ADHD group by the end of the study, while those with ADHD in EC continued to

Effect: improvement; F(6,382)=2.29

Bipolar adolescents with comorbid ADHD who received FFT-A showed an 18% decrease in (hypo)manic symptoms from 9 to 24 months, while those with ADHD who received EC had a 2% increase over the same inte

Effect: improvement; 18% decrease in (hypo)manic symptoms from 9-24 months (FFT-A+ADHD) vs 2% increase (EC+ADHD)

Bipolar adolescents with comorbid ADHD who received FFT-A showed an 18% decrease in (hypo)manic symptoms from 9 to 24 months, while those with ADHD who received EC had a 2% increase over the same inte

Effect: improvement; 18% decrease in (hypo)manic symptoms from 9-24 months (FFT-A+ADHD) vs 2% increase (EC+ADHD)

Bipolar adolescents with comorbid ADHD who received FFT-A showed an 18% decrease in (hypo)manic symptoms from 9 to 24 months, while those with ADHD who received EC had a 2% increase over the same inte

Effect: improvement; 18% decrease in (hypo)manic symptoms from 9-24 months (FFT-A+ADHD) vs 2% increase (EC+ADHD)

Bipolar adolescents with comorbid ADHD who received FFT-A showed an 18% decrease in (hypo)manic symptoms from 9 to 24 months, while those with ADHD who received EC had a 2% increase over the same inte

Effect: improvement; 18% decrease in (hypo)manic symptoms from 9-24 months (FFT-A+ADHD) vs 2% increase (EC+ADHD)

Bipolar adolescents with comorbid ADHD who received FFT-A showed an 18% decrease in (hypo)manic symptoms from 9 to 24 months, while those with ADHD who received EC had a 2% increase over the same inte

Effect: improvement; 18% decrease in (hypo)manic symptoms from 9-24 months (FFT-A+ADHD) vs 2% increase (EC+ADHD)

Bipolar adolescents with comorbid ADHD who received FFT-A showed an 18% decrease in (hypo)manic symptoms from 9 to 24 months, while those with ADHD who received EC had a 2% increase over the same inte

Effect: improvement; 18% decrease in (hypo)manic symptoms from 9-24 months (FFT-A+ADHD) vs 2% increase (EC+ADHD)

Bipolar adolescents with comorbid ADHD who received FFT-A showed an 18% decrease in (hypo)manic symptoms from 9 to 24 months, while those with ADHD who received EC had a 2% increase over the same inte

Effect: improvement; 18% decrease in (hypo)manic symptoms from 9-24 months (FFT-A+ADHD) vs 2% increase (EC+ADHD)

Bipolar adolescents with comorbid ADHD who received FFT-A showed an 18% decrease in (hypo)manic symptoms from 9 to 24 months, while those with ADHD who received EC had a 2% increase over the same inte

Effect: improvement; 18% decrease in (hypo)manic symptoms from 9-24 months (FFT-A+ADHD) vs 2% increase (EC+ADHD)

Bipolar adolescents with comorbid ADHD who received FFT-A showed an 18% decrease in (hypo)manic symptoms from 9 to 24 months, while those with ADHD who received EC had a 2% increase over the same inte

Effect: improvement; 18% decrease in (hypo)manic symptoms from 9-24 months (FFT-A+ADHD) vs 2% increase (EC+ADHD)

Bipolar adolescents with comorbid ADHD who received FFT-A showed an 18% decrease in (hypo)manic symptoms from 9 to 24 months, while those with ADHD who received EC had a 2% increase over the same inte

Effect: improvement; 18% decrease in (hypo)manic symptoms from 9-24 months (FFT-A+ADHD) vs 2% increase (EC+ADHD)

Bipolar adolescents with comorbid ADHD who received FFT-A showed an 18% decrease in (hypo)manic symptoms from 9 to 24 months, while those with ADHD who received EC had a 2% increase over the same inte

Effect: improvement; 18% decrease in (hypo)manic symptoms from 9-24 months (FFT-A+ADHD) vs 2% increase (EC+ADHD)

Bipolar adolescents with comorbid ADHD who received FFT-A showed an 18% decrease in (hypo)manic symptoms from 9 to 24 months, while those with ADHD who received EC had a 2% increase over the same inte

Effect: improvement; 18% decrease in (hypo)manic symptoms from 9-24 months (FFT-A+ADHD) vs 2% increase (EC+ADHD)

Bipolar adolescents with comorbid ADHD who received FFT-A showed an 18% decrease in (hypo)manic symptoms from 9 to 24 months, while those with ADHD who received EC had a 2% increase over the same inte

Effect: improvement; 18% decrease in (hypo)manic symptoms from 9-24 months (FFT-A+ADHD) vs 2% increase (EC+ADHD)

Bipolar adolescents with comorbid ADHD who received FFT-A showed an 18% decrease in (hypo)manic symptoms from 9 to 24 months, while those with ADHD who received EC had a 2% increase over the same inte

Effect: improvement; 18% decrease in (hypo)manic symptoms from 9-24 months (FFT-A+ADHD) vs 2% increase (EC+ADHD)

Bipolar adolescents with comorbid ADHD who received FFT-A showed an 18% decrease in (hypo)manic symptoms from 9 to 24 months, while those with ADHD who received EC had a 2% increase over the same inte

Effect: improvement; 18% decrease in (hypo)manic symptoms from 9-24 months (FFT-A+ADHD) vs 2% increase (EC+ADHD)

Bipolar adolescents with comorbid ADHD who received FFT-A showed an 18% decrease in (hypo)manic symptoms from 9 to 24 months, while those with ADHD who received EC had a 2% increase over the same inte

Effect: improvement; 18% decrease in (hypo)manic symptoms from 9-24 months (FFT-A+ADHD) vs 2% increase (EC+ADHD)

Bipolar adolescents with comorbid ADHD who received FFT-A showed an 18% decrease in (hypo)manic symptoms from 9 to 24 months, while those with ADHD who received EC had a 2% increase over the same inte

Effect: improvement; 18% decrease in (hypo)manic symptoms from 9-24 months (FFT-A+ADHD) vs 2% increase (EC+ADHD)

Bipolar adolescents with comorbid ADHD who received FFT-A showed an 18% decrease in (hypo)manic symptoms from 9 to 24 months, while those with ADHD who received EC had a 2% increase over the same inte

Effect: improvement; 18% decrease in (hypo)manic symptoms from 9-24 months (FFT-A+ADHD) vs 2% increase (EC+ADHD)

Bipolar adolescents with comorbid ADHD who received FFT-A showed an 18% decrease in (hypo)manic symptoms from 9 to 24 months, while those with ADHD who received EC had a 2% increase over the same inte

Effect: improvement; 18% decrease in (hypo)manic symptoms from 9-24 months (FFT-A+ADHD) vs 2% increase (EC+ADHD)

Bipolar adolescents with comorbid ADHD who received FFT-A showed an 18% decrease in (hypo)manic symptoms from 9 to 24 months, while those with ADHD who received EC had a 2% increase over the same inte

Effect: improvement; 18% decrease in (hypo)manic symptoms from 9-24 months (FFT-A+ADHD) vs 2% increase (EC+ADHD)

Bipolar adolescents with comorbid ADHD who received FFT-A showed an 18% decrease in (hypo)manic symptoms from 9 to 24 months, while those with ADHD who received EC had a 2% increase over the same inte

Effect: improvement; 18% decrease in (hypo)manic symptoms from 9-24 months (FFT-A+ADHD) vs 2% increase (EC+ADHD)

Bipolar adolescents with comorbid ADHD who received FFT-A showed an 18% decrease in (hypo)manic symptoms from 9 to 24 months, while those with ADHD who received EC had a 2% increase over the same inte

Effect: improvement; 18% decrease in (hypo)manic symptoms from 9-24 months (FFT-A+ADHD) vs 2% increase (EC+ADHD)

Bipolar adolescents with comorbid ADHD who received FFT-A showed an 18% decrease in (hypo)manic symptoms from 9 to 24 months, while those with ADHD who received EC had a 2% increase over the same inte

Effect: improvement; 18% decrease in (hypo)manic symptoms from 9-24 months (FFT-A+ADHD) vs 2% increase (EC+ADHD)